Texas Pharmacy Loses License Over Risky Drug Fills
Published Date: 4/14/2025
Notice
Summary
Mariste Pharmacy in Texas lost its DEA license because it kept filling risky prescriptions without checking for abuse and broke important drug storage and record rules. They didn’t ask for a hearing to defend themselves, so the suspension and revocation stand. This means Mariste can’t legally handle controlled drugs anymore, protecting public safety starting from May 2024.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA revokes Mariste Pharmacy registration
The Drug Enforcement Administration revoked Mariste Pharmacy's DEA Certificate of Registration No. FM2279431. The final Order revoking the registration is effective May 14, 2025, which means Mariste Pharmacy no longer holds a DEA registration to distribute or dispense controlled substances.
Immediate suspension issued May 20, 2024
On May 20, 2024, the DEA issued an Order to Show Cause and Immediate Suspension of Registration for Mariste Pharmacy under 21 U.S.C. 824(d), finding the continued registration could be an imminent danger to public health or safety. That suspension preceded the final revocation.
DEA denies pending and future Texas registrations
The Order also denies any pending applications of Mariste Pharmacy to renew or modify this registration and denies any other pending application for additional registration in Texas. This denial is part of the final action effective May 14, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17276, Importer of Controlled Substances Application: Biopharmaceutical Research Company
Biopharmaceutical Research Company has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
2026-17285, Importer of Controlled Substances Application: Prof Compounding CTS of Ameri
Prof Compounding CTS of Ameri has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
2026-17275, Catina Allen, N.P.; Decision and Order
Catina Allen, a nurse practitioner from Indiana, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on June 30, 2026. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
Previous / Next Documents
Previous: 2025-06311, Eagle Pharmacy; Decision and Order
Eagle Pharmacy in Houston lost its DEA license because it filled risky prescriptions without fixing warning signs, breaking federal and Texas laws. They missed the deadline to ask for a hearing, so the decision to revoke their registration stands. This means Eagle Pharmacy can no longer legally handle controlled substances, affecting their business and customers immediately.
Next: 2025-06318, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a closed virtual meeting on May 8, 2025, to review important grant applications. This meeting affects researchers seeking funding for diabetes, digestive, and kidney disease studies, ensuring their ideas stay private and protected. No public attendance or money changes are involved, but this review helps decide which projects get support.